A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease

American Journal of Hematology

Volumn 87, Issue 11, 2012, Pages 1017-1021

  Kutlar, Abdullah ^a   Ataga, Kenneth ^b   Reid, Marvin ^c   Vichinsky, Elliott P ^d   Neumayr, Lynne ^d   Blair Britt, Loray ^e   Labotka, Richard ^f   Glass, Jonathan ^g   Keefer, Jeffrey R ^h   Wargin, William A ⁱ   Berenson, Ronald ^j   Perrine, Susan P ^k  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

^e Century Clinical Family Medicine   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ PK PM Associates LLC   (United States)

^j HemaQuest Pharmaceuticals   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMATOLOGIC AGENT; HEMOGLOBIN F; HQK 1001; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE PAIN; CLINICAL ARTICLE; COUGHING; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BIOLOGICAL AVAILABILITY; BUTYRATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTES; FEMALE; FETAL HEMOGLOBIN; HEMATINICS; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84867904678     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23306     Document Type: Article

References (51)

1. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115: 4331-4336.
2. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-769.
3. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical sub-phenotypes. Blood Rev 2006; 21: 37-47.
4. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine 2001; 80: 328-344.
5. Watson J. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci 1948; 215: 419-423.
6. Goldberg MA, Husson MA, Bunn HF. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem 1977; 252: 3414-3421.
7. Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A 1979; 76: 670-672.
8. Perrine RP, Brown MJ, Clegg JB, et al. Benign sickle-cell anaemia. Lancet 1972; 2: 1163-1167.
9. Perrine RP, Pembrey ME, John P, et al. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med 1978; 88: 1-6.
10. Franco RS, Yasin Z, Palascak MB, et al. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 2006; 108: 1073-1076.
11. Perrine SP. Fetal globin stimulant therapies in the beta-hemoglobinopathies: Principles and current potential. Pediatr Ann 2008; 37: 339-346.
12. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005; 129: 465-481.
13. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1995; 325: 11-16.
14. Platt OS, Brambilla DJ, Rosse WF, Milner PF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
15. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
16. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987; 69: 109-16.
17. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
18. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85: 403-408.
19. Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood 1997; 89: 1078-1088.
20. Wang CW, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomized, controlled trial (BABY HUG). Lancet 2011; 377: 1663-1672.
21. Inati A, Koussa S, Taher A, et al. Sickle cell disease; new insights into pathophysiology and treatment. Pediatr Ann 2008; 37: 311-321.
22. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988; 318: 96-99.
23. Steinberg MH. Clinical trials in sickle cell disease: Adopting the combination chemotherapy paradigm. Am J Hematol 2008; 83: 1-3.
24. Koshy M, Dorn L, Bressler L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000; 96: 2379-2384.
25. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003; 102: 3865-3870.
26. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999; 93: 790-797.
27. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin gene expression in the beta-globin disorders. N Engl J Med 1993; 328: 81-86.
28. Ikuta T, Kan Y, Swerdlow PS, et al. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood 1998; 92: 2924-2933.
29. Boosalis MS, Bandyopadhyay R, Bresnick EH, et al. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 2001; 7: 3259-3267.
30. Pace BS, White GL, Dover GJ, et al. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 2002; 100: 4640-4648.
31. Castaneda S, Boosalis MS, Emery D, et al. Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis 2005; 35: 217-226.
32. Perrine SP, Mankidy R, Boosalis MS, et al. Erythroid Krüppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol 2009; 82: 466-476.
33. Perrine SP, Wargin WA, Boosalis MS, et al. Evaluation of safety and pharmacokinetics of sodium 2, 2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single- and repeat-dose studies in healthy volunteers. J Clin Pharm 2011; 51: 1186-1194.
34. Nagel RL, Vichinsky EP, Shah M, et al. F-reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double blind study. Blood 1992; 81: 9-14.
35. Sherwood JB, Goldwasser E, Chilcote R, et al. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 1986; 67: 46-49.
36. Resar LM, Segal JB, Fitzpatric LK, et al. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol 2002; 24: 737-741.
37. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361: 2309-2317.
38. Mankidy R, Faller DV, Mabaera R, et al. Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood 2006; 108: 3179-3186.
39. Chen Z, Luo H, Steinberg MH, Chui DHK. BCL11A represses HBG transcription in K562 cells. Blood Cells Mols Dis 2009; 41: 144-149.
40. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009; 145: 455-467.
41. Miller BA, Salameh M, Ahmed M, et al. Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. Blood 1987; 70: 716-720.
42. Pembrey ME, Wood WG, Weatherall DJ, Perrine RP. Fetal haemoglobin production and the sickle gene in the oases of eastern Saudi Arabia. Br J Haematol 1978; 40: 415-429.
43. Dover GJ, Smith KD, Chang YC, Purvis S, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992; 80: 816-824.
44. Chang YC, Smith KD, Moore RD, et al. An analysis of fetal hemoglobin variation in sickle cell disease: The relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender and age. Blood 1995; 85: 1111-1117.
45. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: Genetic determinants of response to hydroxyurea SNPs, hydroxyurea and HbF in sickle cell anemia. Pharmacogenomics J 2007; 7: 386-394.
46. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011; 118: 19-27.
47. Perrine SP, Faller DV, Shen L, et al. HQK-1001 has additive HbF-inducing activity in combination with hydroxyurea and decitabine. Blood 2009; 114: 403.
48. Sankaran VG, Xu J, Orkin SH. Transcriptional silencing of fetal hemoglobin by BCL11A. Ann NY Acad Sci 2010; 1202: 64-68.
49. Sobash P, Kutlar F, Brown HC, et al. BCL11A polymorphism and HbF response to hydroxyurea in adult patients with sickle cell disease. Blood 2011; 118: 484.
50. Lavelle D, Saunthararajah Y, Vaitkus K, et al. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Translational Med 2010; 8: 1-8.
51. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.